Zepbound® (tirzepatide) KwikPen 15 mg/0.6 mL

Product Description: Zepbound® (tirzepatide) KwikPen 15 mg/0.6 mL

Zepbound® (tirzepatide) is a once-weekly injectable prescription medication indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management. The 15 mg/0.6 mL KwikPen is the maximum recommended therapeutic dose, utilized by patients who have successfully titrated through lower strengths and require this potency for maximal metabolic effect and weight loss.

Product Specifications

• Dosage Strength: 15 mg per 0.6 mL.

• Presentation: KwikPen (Multi-dose pre-filled delivery system).

• Indication: Chronic weight management in adults with an initial BMI of $\ge 30\text{ kg/m}^2$ (obesity) or $\ge 27\text{ kg/m}^2$ (overweight) with at least one weight-related comorbid condition.

• Administration: Subcutaneous injection once weekly in the abdomen, thigh, or upper arm.

• Mechanism of Action: A potent dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It modulates key metabolic pathways to induce significant weight loss by slowing gastric emptying and enhancing satiety.

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

In rodent studies, tirzepatide has been shown to cause thyroid C-cell tumors. It is unknown whether Zepbound causes these tumors, including medullary thyroid carcinoma (MTC), in humans. Zepbound is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Clinical Considerations

• High-Dose Tolerance: At the 15 mg dosage, patients may report a higher frequency or severity of gastrointestinal adverse events, such as nausea, vomiting, or diarrhea. Ongoing clinical monitoring is advised to manage symptoms and ensure adequate hydration.

• Device Handling: As a multi-dose device, it is critical that patients use a new, sterile needle for every weekly administration and follow the priming instructions provided with the pen to ensure precise dosing.

• Contraindications: History of MTC/MEN 2; known serious hypersensitivity to tirzepatide or any product components.

• Hypoglycemia: The risk of hypoglycemia is elevated when used in combination with insulin or insulin secretagogues; clinicians should evaluate the necessity of dosage adjustments for these concurrent medications.

Storage and Handling

• Before First Use: Store in the refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze.

• After First Use: The pen may be stored at room temperature (not exceeding 86°F or 30°C) for up to 30 days.

• Stability: Protect from direct light and excessive heat. Inspect the solution before each use; it must be clear and colorless to slightly yellow. Do not use if the solution is cloudy, discolored, or contains particulate matter.

Disclaimer: This information is provided for professional reference only and does not constitute medical advice, diagnosis, or treatment. Always refer to the official FDA-approved Prescribing Information, Medication Guide, and Instructions for Use for comprehensive clinical protocols.